Your Health, We Care
Alpelisib is indicated in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endocrine-based regimen.
from FDA,2022.11
By specifically inhibiting PIK3CA mutations, Apelis provides a novel therapeutic strategy for patients with HR/HER2- advanced breast cancer.What diseases can be treated with Alpeli···【more】
Article source：Lucius LaosRelease date：2024-08-23Recommended：100
Alpelisib fills a gap in the treatment of HR/HER2- breast cancer, particularly in patients with PIK3CA mutations, and the combination of fulvestrant improves efficacy.Who is Alpeli···【more】
Article source：Lucius LaosRelease date：2024-08-23Recommended：96
For patients with advanced HR/HER2- breast cancer, the combination of Alpelisib and fulvestrant is a precision treatment for PIK3CA mutations.Who is Alpelisib for?Alpelisib is suit···【more】
Article source：Lucius LaosRelease date：2024-08-23Recommended：93
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
